December 4, 2018. We all want to help these patients, but new treatments need to provide a real benefit. The questions that we need to answer are does this device help patients and should patients continue to have the option of receiving an experimental treatment as part of a clinical trial, or should they pay for an experimental treatment that has been described as a breakthrough?
Read More »On Medical Treatments & Products
Is TMS Proven Effective for Depression?
This report will examine how TMS became a frequently used treatment for depression in the United States despite what the research of the last decade shows about its very questionable effectiveness.
Read More »NCHR Testimony on Antidepressant Brexanolone for Postpartum Depression
National Center for Health Research testifies against the approval of a new first of its kind drug for postpartum depression called Brexanolone.
Read More »NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression
November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.
Read More »NCHR Testimony on the Opioid Oliceridine
October 11, 2018. There are many unanswered questions about what dosages work and are safe for which patients under which conditions. We all know that is an epidemic of opioid use, so these questions must be answered before a decision is made about whether or not to approve oliceridine.
Read More »